Voyageur Pharmaceuticals Ltd. (VM-TSXV / VYYRF-PINK)

Voyageur Pharmaceuticals Ltd.
Dome Tower 800, 333 7 Ave. S.W.
Calgary, Alberta T2P 2Z1
Phone: (877) 398-6866
https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. (“Voyageur” or “the Company”) is a Canadian specialty pharmaceutical company developing and commercializing high-performance contrast media for diagnostic imaging. With full vertical integration—from raw material extraction to finished product manufacturing—the Company controls its supply chain, giving it cost and reliability advantages in a market facing global shortages and rising input costs. Voyageur’s core operations, which have been initiated, center on pharmaceutical-grade barite from its Frances Creek deposit in British Columbia, which is used to produce barium contrast agents for gastrointestinal (GI) imaging. Using third party manufacturing and imported barite, the Company has launched multiple Health Canada-approved products, including SmoothX®, SmoothHD®, SmoothLD®, VisionHD®, and VisionLD®, with international distribution contracts under development. Beyond barium, Voyageur is advancing iodine-based contrast agents and its own iodine Active Pharmaceutical Ingredient (API) to enable full integration in iodine manufacturing. The Company expects to advance iodine brine resources as part of a large Oklahoma/Texas manufacturing hub. Voyageur owns two other mineral assets with spinout potential—Jubilee Mountain (zinc-copper-silver-lead) and the ULI Project in Utah (lithium, iodine-, bromine-, and magnesium-rich brines). Backed by an experienced leadership team and a top-tier scientific advisory board, the Company is pursuing a regulatory strategy designed to minimize risk across Canada, the U.S., and Europe and is well positioned for growth in a global imaging market valued at $6.3 billion and projected to reach $12.6 billion by 2032.

* Updated on October 30, 2025.